Mean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease

被引:0
|
作者
Cho, Eun Hye [1 ]
Kim, Jee Ah [1 ]
Park, Min-Seung [1 ]
Kwon, Min-Jung [1 ]
Park, Hyosoon [1 ]
Woo, Hee-Yeon [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Lab Med, Seoul, South Korea
来源
PLOS ONE | 2025年 / 20卷 / 02期
关键词
D O I
10.1371/journal.pone.0318847
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction Non-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Accurate assessment of liver fibrosis is essential for the prognosis and management of NAFLD. Mean platelet volume (MPV), an index of platelet activation, has been associated with liver fibrosis in various chronic liver diseases; however, its role in NAFLD remains uncertain. Methods This study analyzed data from 70,830 patients with NAFLD who underwent a comprehensive health examination between 2015 and 2019. Patients were stratified into three groups based on the fibrosis-4 (FIB-4) index: low (<1.30), indeterminate (1.30-2.67), and high (>2.67). We evaluated the differences in MPV among these groups and analyzed the association between MPV and the FIB-4 index. Results MPV varied significantly across the three groups categorized by the FIB-4 index (p < 0.001). Additionally, a weak but statistically significant positive correlation was observed between MPV and the FIB-4 index (rho = 0.170, p < 0.001). Multivariable linear regression adjusted for multiple covariates showed that MPV remained significantly associated with the FIB-4 index (beta = 0.01, p < 0.001). Conclusions MPV may serve as a supplementary non-invasive marker for assessing liver fibrosis in patients with NAFLD. Further studies are required to validate these findings and explore the utility of MPV in conjunction with other non-invasive markers.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Cognitive impairment and liver fibrosis in non-alcoholic fatty liver disease
    Parikh, Neal S.
    Wahbeh, Farah
    Tapia, Christopher
    Ianelli, Mallory
    Liao, Vanessa
    Jaywant, Abhishek
    Kamel, Hooman
    Kumar, Sonal
    Iadecola, Costantino
    BMJ NEUROLOGY OPEN, 2024, 6 (01)
  • [22] Metalloproteinases in non-alcoholic fatty liver disease and their behavior in liver fibrosis
    Barchuk, Magali
    Schreier, Laura
    Berg, Gabriela
    Miksztowicz, Veronica
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2020, 41 (01)
  • [23] Laboratory diagnostics of liver fibrosis and non-alcoholic fatty liver disease
    von Eckardstein, Arnold
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2014, 38 (02): : 75 - 85
  • [24] Diabetes as a Risk Factor of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease
    Trikola, Artemis
    Papastergiou, Basilios
    Mela, Maria
    Christidou, Angeliki
    Mountaki, Aikaterini
    Koustenis, Kanellos
    Veretanos, Christos
    Karaouzas, Lazaros
    Paparizou, Athanasia
    Arvanitis, Konstantinos
    Archavlis, Emmanouel
    Katopodi, Konstantina
    Viazis, Nikolaos
    Mantzaris, Gerassimos J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S973 - S973
  • [25] Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging
    Li, Yuan
    Adeniji, Nia T.
    Fan, Weiguo
    Kunimoto, Koshi
    Torok, Natalie J.
    AGING AND DISEASE, 2022, 13 (04): : 1239 - 1251
  • [26] Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis
    Gisondi, P.
    Barba, E.
    Girolomoni, G.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (02) : 282 - 287
  • [27] Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
    Hardy, Timothy
    Zeybel, Mujdat
    Day, Christopher P.
    Dipper, Christian
    Masson, Steven
    McPherson, Stuart
    Henderson, Elsbeth
    Tiniakos, Dina
    White, Steve
    French, Jeremy
    Mann, Derek A.
    Anstee, Quentin M.
    Mann, Jelena
    GUT, 2017, 66 (07) : 1321 - 1328
  • [28] Impact of non-alcoholic fatty liver disease on liver volume in humans
    Bian, Hua
    Hakkarainen, Antti
    Zhou, You
    Lundbom, Nina
    Olkkonen, Vesa M.
    Yki-Jarvinen, Hannele
    HEPATOLOGY RESEARCH, 2015, 45 (02) : 210 - 219
  • [29] PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE, HIGH-RISK NON-ALCOHOLIC STEATOHEPATITIS, AND LIVER FIBROSIS IN PATIENTS WITH OSTEOARTHRITIS
    Kalligeros, Markos
    Vassilopoulos, Athanasios
    Vassilopoulos, Stephanos
    Wands, Jack R.
    Promrat, Kittichai
    HEPATOLOGY, 2023, 78 : S1034 - S1035
  • [30] Predictors of non-alcoholic steatohepatitis and fibrosis in non-alcoholic fatty liver disease.
    Pong, JP
    Elariny, H
    Younoszai, A
    HEPATOLOGY, 2002, 36 (04) : 407A - 407A